Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Pipeline Review, H1 2016 - Product Image

Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Pipeline Review, H1 2016

  • ID: 3802778
  • Report
  • 37 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Agilvax, Inc.
  • Bavarian Nordic A/S
  • F. Hoffmann-La Roche Ltd.
  • Trellis Bioscience, Inc.
  • MORE
Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Pipeline Review, H1 2016

Summary

‘Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Pipeline Review, H1 2016’, provides in depth analysis on Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted pipeline therapeutics.

The report provides comprehensive information on the Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G)
- The report reviews Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted therapeutics and enlists all their major and minor projects
- The report assesses Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Agilvax, Inc.
  • Bavarian Nordic A/S
  • F. Hoffmann-La Roche Ltd.
  • Trellis Bioscience, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) Overview

Therapeutics Development

Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Products under Development by Stage of Development

Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Products under Development by Therapy Area

Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Products under Development by Indication

Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Pipeline Products Glance

Early Stage Products

Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Products under Development by Companies

Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Products under Development by Universities/Institutes

Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Companies Involved in Therapeutics Development

Agilvax, Inc.

Bavarian Nordic A/S

Emergent BioSolutions Inc.

F. Hoffmann-La Roche Ltd.

Trellis Bioscience, Inc.

Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Drug Profiles

Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MVA-RSV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus (virus like particle) vaccines - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRL-3D3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Dormant Projects

Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Featured News & Press Releases

May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations

Aug 18, 2015: Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN in Respiratory Syncitial Virus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 37List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Agilvax, Inc., H1 2016

Pipeline by Bavarian Nordic A/S, H1 2016

Pipeline by Emergent BioSolutions Inc., H1 2016

Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Pipeline by Trellis Bioscience, Inc., H1 2016

Dormant Projects, H1 2016 33List of Figures

Number of Products under Development for, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Agilvax, Inc.
  • Bavarian Nordic A/S
  • F. Hoffmann-La Roche Ltd.
  • Trellis Bioscience, Inc.
  • MORE
Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by Companies and remaining by the Universities/Institutes. The author's latest report Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H1 2016, outlays comprehensive information on the Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) Respiratory syncytial virus G protein is a protein produced by respiratory syncytial virus. It attaches the virion to the host cell membrane by interacting with heparan sulfate. It interacts with host CX3CR1, the receptor for the CX3C chemokine fractalkine, to modulate the immune response and facilitate infection. Secreted glycoprotein G helps RSV escape antibody-dependent restriction of replication by acting as an antigen decoy and by modulating the activity of leukocytes bearing Fc gamma receptors. The molecules developed by Companies in Phase I and Preclinical stages are 1 and 6 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Agilvax, Inc.
Bavarian Nordic A/S
Emergent BioSolutions Inc.
F. Hoffmann-La Roche Ltd.
Trellis Bioscience, Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll